|
|
8-Night Holland & Belgium Tulip Time CME AWAY® River Cruise - Infectious Disease, Neonatal Care, Space Travel and Motor Vehicle Accidents
DINING
- All meals onboard, prepared using the finest and freshest ingredients
- Captain’s Welcome and Farewell Receptions
- Welcome and Farewell Gala Dinners
- Unlimited beverages onboard, including fine wine, beer, spirits, specialty coffee and tea, soft drinks and mineral water
EXCURSIONS
- 6 days of excursions, including “Choice Is Yours” options, all fully hosted by English-speaking Local experts
- Guided “Do as the Locals Do,” “Village Day,” “Go Active” and “Ge... |
|
|
9-Night Kenya CME AWAY® Land Tour - Neurology and Orthopedics: Brain vs Brawn
The concept of the safari was born in Kenya where in Kiswahili the word
safari means "journey”. East Africa has the reputation as the quintessential safari destination for good reason. The region’s dramatic contrasts and endless array of ecosystems showcases a variety of wildlife, making this one of the top destinations for African safari vacationers. |
|
|
7-Night Jamaica CME AWAY® Resort - Dermatology & Aesthetic Medicine: Recent Advancements & Exciting Developments
The all-new Sandals South Coast is the perfect combination of European civility in anall-beachfront resort. From all-new Over-the-Water Bungalows, an overwater bar, and a romantic Over-the-Water Chapel, Sandals South Coast brings guests closer than ever to the water. Set on a 2-mile stretch of Jamaica's south coast's most pristine white-sand beach and nestled within a 500-acre nature preserve, this spectacular seaside oasis features three distinctive European Villages. Relax by one of three po... |
|
|
13-Night Dubai, Abu Dhabi & Muscat CME AWAY® Land Tour - Emergency Medicine: Practical Advice and Contemporary Driven Evidence for Common Presentations
Dubai is a stirring alchemy of profound traditions and ambitious futuristic vision wrapped into starkly evocative desert splendour. Proudly modern and cosmopolitan, Abu Dhabi is the UAE's forward-thinking cultural heart where nothing stands still – except perhaps the herons in its mangroves. Scenically wedged between mountains and ocean, with old forts and excellent museums, an opera house and flower-filled parks, the gentle city of Muscat is a delight to visit. Its name means ‘safe anchor... |
|
|
10-Night Essence of Peru CME AWAY® Land Tour
Peru is truly one of the treasures of South America. Travel through this intriguing land visiting some of the world’s most legendary sites, including Machu Picchu, the “Lost City of the Incas”. Few places can actually be called a “lost city”. Yet, Machu Picchu remained undiscovered by the Spanish Conquistadors and unknown to the outside world until 1911. Today, travellers come from around the globe to experience the most spectacular sight on the South American continent. Built at th... |
|
|
5-Night Banff CME AWAY® Resort - Forensic Dentistry, Domestic Violence, Oral Cancer and HPV and Psychiatric Illness and Dentistry: Challenges for Oral Care
Moose Hotel & Suites
The design of The Moose is “mountain elegance”, with warm, rich, natural materials. Located a 1 minute walk from the heart of downtown Banff, the Moose Hotel & Suites features 174 air conditioned guests rooms, with a combination of One and Two Bedroom Suites and hotel rooms. Amenities include the Meadow Spa & Pools with 10 treatment rooms and private outdoor hot pool, a bright indoor swimming pool and exercise room on the 3rd floor, and 2 spectacular rooftop hot pools... |
|
|
10-Night France, Spain & Portugal CME AWAY® Cruise - State of the Art Management of Pain, Wellness & Practical Mindfulness
Southampton, England • Bordeaux, France • St. Jean De Luz, France • Bilbao, Spain • Gijon, Spain • La Coruna, Spain • Porto (Leixoes), Portugal •
Lisbon, Portugal |
|
|
11-Night Egypt & Israel CME AWAY® Cruise
Athens (Piraeus), Greece • Alexandria, Egypt • Port Said, Egypt • Jerusalem (Ashdod), Israel • Haifa, Israel • Limassol, Cyprus • Athens (Piraeus), Greece
|
|
|
13-Night British Isles CME AWAY® Cruise
Southampton, England • Edinburgh (Leith), Scotland • Dundee, Scotland • Invergordon, Scotland • Belfast, Northern Ireland • Glasgow (Greenock), Scotland • Douglas, Isle Of Man • Dublin, Ireland |
|
|
10-Night Adriatic & Aegean Array CME AWAY® Cruise
Rome (Civitavecchia), Italy • Positano, Italy • Syracuse (Sicily), Italy • Crotone (Calabria), Italy • Dubrovnik, Croatia • Venice, Italy • Katakolon,
Greece • Santorini, Greece • Athens (Piraeus), Greece |
|
|
7-Night St. Lucia CME AWAY® Resort - Forensic Dentistry, Domestic Violence, Oral Cancer and HPV and Psychiatric Illness and Dentistry: Challenges for Oral Care
Pigeon Island Gros Islet, St. Lucia
An idyllic all-inclusive resort located on its very own peninsula, Sandals Grande St. Lucian is often described as the “closest vacation to a picture-perfect postcard.” Cradled to the west by Rodney Bay – boasting the calmest waters in all of Saint Lucia – and to the east by the majestic Atlantic Ocean, this magnificent adults-only resort showcases awe-inspiring panoramic views and Over-The-Water Bungalows that will linger in your heart forever. V... |
|
|
18-Night South America CME AWAY® Cruise - Osteoarthritis, Medical Cannabis, Mood Disorders, Elder Care, Concussions, Exercise and Pregnancy and Pain Management
Bridgetown, Barbados • Willemstad, Curaçao • Oranjestad, Aruba • Cartagena, Columbia • Panama Canal Transit • Manta, Ecuador • Salaverry, Peru • Lima (Callao), Peru • Arica, Chile • Valparaiso, Chile |
|
|
10-Night Italy & France CME AWAY® Cruise - Endodontics: What’s Old, What’s New & What Works
Rome (Civitavecchia), Italy • Florence/Pisa(La Spezia), Italy • Cannes, France • Provence (Toulon), France • Barcelona, Spain • Cagliari, Sardinia • Sicily (Messina), Italy • Naples, Italy |
|
|
11-Night Emblematic East Coast CME AWAY® Cruise - Updates in Vascular Diseases & Endocrinology
New York, New York • Hamilton, Bermuda • St. George, Bermuda • Halifax, Nova Scotia • Sydney, Nova Scotia • Saguenay, Quebec • Quebec
City, Quebec • Montreal, Quebec
|
|
|
19-Night Intensive Australia CME AWAY® Cruise - Parkinson’s Disease, Concussions, Seizure Disorders, MS, Pain Management & Perspectives of a Coroner
Fremantle (Perth), Australia • Abrolhos Islands, Australia • Dirk Hartog Island, Australia • Exmouth, Australia • Montebello Islands, Australia • Dampier Archipelago, Australia • Lacepedes Islands, Australia
• Buccaneer Archipelago Region, Australia • Hunter River Region, Australia • King George River (Kimberley), Australia • Wyndham, Australia • Matakus Island, Indonesia • Darwin, Australia |
|
|
15-Night Intensive Norway CME AWAY® Cruise
London (Greenwich), England • Newcastle, England • Stavanger, Norway • Bergen, Norway • Flåm, Norway • Nordfjordeid, Norway • Geiranger, Norway • Hellesylt, Norway • Molde (Romsdal), Norway • Leknes (Vestvågøy), Norway • Narvik, Norway • Honningsvag (North Cape), Norway • Alta, Norway • Tromsø, Norway • Oslo, Norway |
|
|
12-Night Scandinavia & Russia CME AWAY® Cruise
Amsterdam, Netherlands ● Ronne, Bornholm, Denmark ● St. Petersburg, Russia ● Tallinn, Estonia ● Helsinki, Finland ● Stockholm, Sweden ● Copenhagen, Denmark |
|
|
12-Night British Isles CME AWAY® Cruise - Peri-Menopause, Menopause, Contraception, Abnormal Uterine Bleeding, Sexual Health & Sexually Transmitted Infections
Amsterdam, Netherlands • Dover, England • Portland, Dorset, UK • Cork (Cobh), Ireland • Dublin, Ireland • Liverpool, England • Belfast, Northern Ireland • Glasgow (Greenock), Scotland • Lerwick/Shetland, Scotland |
|
|
7-Night Caribbean CME AWAY® Cruise
Fort Lauderdale, Florida • Nassau Bahamas • Puerto Costa Maya, Mexico • Cozumel, Mexico • George Town, Grand Cayman |
|
|
11-Night Svalbard CME AWAY® Cruise
Longyearbyen, Norway • Svalbard Northern Region, Norway • Svalbard Southern Region, Norway • Bear Island (Svalbard), Norway • Skarsvag (Nordkapp), Norway • Gjesværstappan Islands, Norway • Tromsø, Norway • Oslo, Norway |
|
|
10-Night Alaska CME AWAY® Cruise
Seattle, Washington • Ketchikan, Alaska • Juneau, Alaska • Haines, Alaska • Icy Strait Point (Hoonah), Alaska • Sitka, Alaska • Victoria, British Columbia |
|
|
16-Night New Zealand CME AWAY® Cruise
Auckland, New Zealand • Bay Of Islands, New Zealand • Kingston, Norfolk Island, New Zealand • New Plymouth, New Zealand • Milford Sound, New Zealand • Dunedin, New Zealand • Akaroa, New Zealand • Wellington, New Zealand • Nelson, New Zealand • Picton, New Zealand • Napier, New Zealand • Tauranga, New Zealand |
|
|
7-Night Jamaica CME AWAY® Resort - Pearls for Dealing with Rheumatic Diseases, Common Sleeping Disorders & Psychiatric Problems in Family Practice
The all-new Sandals South Coast is the perfect combination of European civility in anall-beachfront resort. From all-new Over-the-Water Bungalows, an overwater bar, and a romantic Over-the-Water Chapel, Sandals South Coast brings guests closer than ever to the water. Set on a 2-mile stretch of Jamaica's south coast's most pristine white-sand beach and nestled within a 500-acre nature preserve, this spectacular seaside oasis features three distinctive European Villages. Relax by one of three po... |
|
|
Modern Medical Glaucoma Exploring the Trends
This webcast focuses on the newest therapies in glaucoma management and how their mechanisms of action and efficacy compares to traditional prostaglandins. The webcast also includes case discussions. Please also enjoy the perviously recorded question-and-answer session with Drs. Ian Benjamin Gaddie and Gagan Sawhney! |
|
|
Visualizing the Future of Presbyopia
Presbyopia is a natural result of aging, and eventually affects all individuals who reach an advanced age. This webinar includes discussions on the shortcomings of current treatments, clinical trial data on the emerging pharmaceutical options for the treatment of presbyopia, and patient selection for these novel therapies. |
|
|
International Experiences with New Presbyopia-Correcting IOLs – Enduring
This course is designed to educate ophthalmologists on the use of next generation presbyopia-correcting IOLs, including hybrids of advanced monofocals, EDOFs and multifocals from multiple manufacturers. Featuring first-hand accounts from an international group of faculty, US doctors will be able to learn about the next generation IOL designs and outcomes through real-world cases and group discussion. |
|
|
2020 Global Consensus on Corneal Irregularity
A panel of experts in ophthalmology from around the globe offer recommendations for defining, diagnosing, and treating irregular corneas.
Define etiology of irregular corneas, including natural occurring, surgically induced, disease, and/or trauma
Describe the prevalence of these types of irregular corneas’ etiology in various geographic regions and patient populations
Identify specific metric levels (surface regularity index and/or higher order aberrations) for diagnosing various grade... |
|
|
Clinical and Pathological Benefits of Photobiomodulation
Join these experts from around the globe as they discuss the impact of dry age-related macular degeneration (AMD) and geographic atrophy (GA), the limitations of currently available treatments, and how novel therapies under investigation may have the potential to improve vision and quality of life for patients with dry AMD and GA. |
|
|
Photodynamic Therapy in 2020 and Beyond: Current Concepts for Real-World Use
Verteporfin for photodynamic therapy (PDT) has been in commercial use as a treatment for retinal disorders for several decades. Multiple studies have suggested a combination of anti-VEGF agents with PDT provides advantages over anti-VEGF monotherapy for polypoidal choroidal vasculopathy, but in wet AMD, the combination of PDT and anti-VEGF is not as clear-cut. This activity includes expert discussions on real-world clinical scenarios in which the use of PDT alone or in combination with anti-VE... |
|
|
Understanding, Diagnosing, and Treating Neurotrophic Keratitis in 2020
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments. This supplement features four experts in neurotrophic keratitis who review important issues related to managing patients, including the scope and causes of th... |
|
|
Beyond the Anti-VEGFs: An Update on Current and Future AMD Treatment Strategies
The current state of neovascular age-related macular degeneration (nAMD) treatment in terms of anti-VEGF agents and the treatments expecting FDA approval on the near future are highlighted in this supplement. Faculty members also share their experiences in caring for patients during a pandemic. |
|
|
Targeting the Trabecular Meshwork: Incorporating New Outflow Drugs Into Glaucoma Care
Glaucoma is seeing a resurgence in innovative therapeutic developments. The recent approval of two drugs in novel classes for IOP reduction in eyes with ocular hypertension or open-angle glaucoma utilizes unique mechanisms of action not previously available with existing drug choices. This activity will provide education on the efficacy, safety, and mechanism of action of these two new drugs and how they compare to traditional glaucoma treatments. |
|
|
The Role of the Optometrist in the Evolving Management of Diabetic Retinopathy
The content featured in this supplement highlights the crucial role that optometrists play in educating patients with diabetes about the potential ocular complications of their systemic disorder, the additional care that must be addressed when undergoing ocular surgery (ie, cataract), and the benefits of diabetic eye exams and early treatment.
|
|
|
Targeting the Trabecular Meshwork: Collaborative Glaucoma Care
This supplement focuses on the comanagement of patients with glaucoma, specifically those who may be candidates for microinvasive glaucoma surgery procedures (MIGS) that target the trabecular meshwork, and the ways in which optometrists and ophthalmologists collaborate to provide the best pre- and postoperative care for these patients. |
|
|
Epidemiology of Dry AMD and GA
Geographic atrophy (GA) is an advanced form of age-related macula degeneration (AMD) for which there is currently no treatment approved by the US FDA. This supplement summarizes the latest information on GA, including the investigative therapies showing positive outcomes in clinical trials and insight from the expert faculty who share their expertise related to the optimal imaging modalities for evaluating GA and case studies. |
|
|
VBS Fellows Foray 2020
This CME-accredited program, originally planned for the 2020 VBS Annual Meeting, is now digital! Carefully selected cases will be presented by fellows from around the globe. Retina cases you would not believe! Real-world treatment strategies will be enthusiastically discussed among the esteemed panel members.
This truly unique series is designed for fellows, residents, and eye care specialists who recently entered practice and are involved in the management of patients with vitreoretinal di... |
|
|
Photodynamic Therapy: A Look at How This Treatment Fits Into Today’s Retina Practice
Eye care professionals may not know how to effectively identify patients in clinic who will benefit from Photodynamic Therapy (PDT), including those with persistent disease activity. This webinar includes discussions on real-world clinical scenarios in which the use of photodynamic therapy alone or in combination with anti-VEGFs can be a more efficacious treatment option than using anti-VEGFs alone, particularly in the setting of persistent disease activity.
|
|
|
Sustained Delivery of Anti-VEGF Agents: The Port Delivery System with Ranibizumab for the Treatment of Neovascular AMD
Arshad M. Khanani, MD, MA, and Peter A. Campochiaro, MD, discuss the latest available data on innovative sustained-release therapies for neovascular age-related macular degeneration, with a focus on the port delivery system with ranibizumab. |
|
|
Sustained Delivery of Anti-VEGF Agents: Gene Therapy for the Treatment of Neovascular AMD
Arshad M. Khanani, MD, MA, discusses with Christina Y. Weng, MD, MBA, how trial results differ from real-world experience with anti-VEGF injections of patients with neovascular age-related macular degeneration, and how gene therapy may fill various unmet needs in treating this disease. |
|
|
Sustained Delivery of Anti-VEGF Agents: Surgical Videos Highlighting Key Techniques
Arshad M. Khanani, MD, MA, and Carl D. Regillo, MD, discuss the current state of neovascular age-related macular degeneration treatments, the benefits of sustained-delivery of anti-VEGF agents, and additional treatments in development. This webinar also features surgical videos highlighting key techniques. |
|
|
Newest Available Treatments and Compounds in Development
Arshad M. Khanani, MD, MA; and Veeral Sheth, MD, discuss the current treatment regimens of patients with neovascular AMD and compare how disease management may change with therapies expected to gain FDA approval in the near future.
|
|
|
Wet AMD: Frequency of Dosing and Impact on Patient Outcomes
This program, featuring Arshad M. Khanani, MD, MA; and Diana V. Do, MD, highlights how dosing frequency for the treatment of wet AMD is changing based on pivotal clinical trials and real-world experience. They also discuss how the evolving treatment regimens may improve patient outcomes and help overcome challenges faced by patients and retina specialists with monthly dosing. |
|
|
The AMD Treatment Burden: The Problem and Possible Solutions
Arshad M. Khanani, MD, MA; and Nancy M. Holekamp, MD, review how the treatment of neovascular AMD has changed over the years, from thermal laser to different dosing strategies of anti-VEGFs, plus real-world experience with these regimens. They also discuss novel investigational therapies and how they are expected to have a positive impact on the lives of retina patients. |
|
|
What’s Next for nAMD? A Focus on Therapies in the Pipeline
Newer classes of drugs are being evaluated to treat age-related macular degeneration (AMD), along with longer duration of currently approved drugs. This supplement reviews the current status of AMD treatments and improved diagnostic technologies, with a focus on therapies in the pipeline. |
|
|
Neurotrophic Keratitis: Old Problem, New Solutions
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments. |
|
|
Neurotrophic Keratitis: Disease Classifications and Therapy Options
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments.
This webinar features four experts in neurotrophic keratitis who will discuss disease classification, practice patterns, and traditional therapies, as well... |
|
|
Retina Practice: Anti-VEGF Access and Reimbursement
This webinar is designed to address the challenges related to anti-VEGF access in retina practices. Hosted by retina specialists and retinal practice CEOs, the program will tackle both clinical and business-related issues including step therapy, MACRA/MIPS, payor-related obstacles, and more. A previously recorded live question-and-answer session will answer many of your questions and concerns. |
|
|
Addressing Challenges With Anti-VEGF Access
This webinar is designed to address the challenges related to anti-VEGF access in retina practices. Hosted by retina specialists and retinal practice CEOs, the program will tackle both clinical and business-related issues including step therapy, MACRA/MIPS, payor-related obstacles, and more. A previously recorded live question-and-answer session will answer many of your questions and concerns. |
|
|
The Business of Medical Retina: Overcoming Payor Challenges
Anti-VEGF therapy has revolutionized retinal care and turned many unavoidable blinding diseases into pathologies that can be controlled by restoring and preserving vision. Yet as the use of anti-VEGF medications continues to grow, so do the challenges of access to these medications. The following content showcases the challenges faced by physicians, practice administrators, and payors in the journey to providing quality care of patients with retinal disease. |
|
|
Exploring Emerging Trends in Medical Glaucoma Management
This webinar focuses on the newest therapies in glaucoma management and how their mechanisms of action and efficacy compares to traditional prostaglandins. The webinar also includes case discussions. |
|